Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Evaluation of synaptic scaling in Huntington disease mice

FY 2013-14

Summary
Huntington disease is a genetic disorder caused by the inheritance of at least one mutated version of the huntingtin gene. Age of onset of Huntington disease is typically from the mid thirties to the late fourties, with motor, psychiatric and cognitive symptoms becoming progressively worse and culminating in death 15 to 20 years after disease onset. Disease onset is defined by the appearance of overt motor symptoms, most noticeably chorea: sudden, uncontrollable movements. Psychiatric symptoms begin 15 years before the onset of chorea and include anxiety, depression, paranoia, among other symptoms. They impact both the quality of life of patients and their ability to stay in the workforce, and are thought to be caused by malfunctioning connections between brain cells. Information in the brain is coded by the strength of the connections between cells. Through a process known as synaptic plasticity the connections between cells whose activity is often linked will increase, and the connections between cells whose activity is rarely linked will decrease. The strength of connections between these cells must be kept within a certain range. Cells which are too strongly connected will generate epileptic seizures, and cells which are too weakly connected will die. A group of processes known collectively as homeostatic plasticity work to keep the strength of connections between brain cells within this range. One of these processes is synaptic scaling, in which high levels of activity in a network of cells causes the strength of connections between all of the cells to decrease, and low levels of activity in a network causes the strength of connections between all of the cells to increase. Since some of the molecules whose function is changed in Huntington disease are also thought to to be involved in homeostatic plasticity, we suggest that homeostatic plasticity may be abnormal in Huntington disease. We will test this by growing cells from YAC128 mice, which carry mutant copies of the huntingtin gene, and FVB mice, which carry normal versions of the huntingtin gene, in dishes for three weeks. We will grow cells from two brain areas, the cortex and the striatum, the connections between which are especially badly affected in Huntington disease. We will then mix either tetrodotoxin, which will decrease the activity of the cells, bicuculline, which will increase the activity of the cells, or water, which should have no effect on the activity of the cells, into the cells' growth medium and let them grow under these conditions for 48 hours. After this we will measure the strength of the connections between the cells. We will do this in two ways: we will label certain molecules which are involved in transmitting information between cells and measure how many of them there are at the sites where cells connect with each other, and we will measure the electrical signals which are transmitted between cells. We will treat cells some cells with brain-derived neurotrophic factor, a molecule which is produced less by the brain cells of Huntington disease sufferers and is thought to be involved in controling homeostatic plasticity, to try to return homeostatic plasticity in cells from YAC128 to its healthy form. Understanding the biology underlying the early psychiatric symptoms of Huntington disease will allow us to develop new drugs to treat these symptoms. This will benefit Huntington disease sufferers by improving their quality of life. It will also benefit their social circle, as psychiatric disturbances can be disruptive to friends, family and loved ones as well as to the affected individual. Finally, it will benefit society by allowing Huntington disease sufferers to remain at work, contributing to the economy instead of incurring care costs, longer.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
311804
Name
Smith-Dijak Amy I
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluation of synaptic scaling in Huntington disease mice
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Ampa Receptor; Homeostatic Plasticity; Huntington Disease; Neurodegeneration; Neuroscience; Nmda Receptor; Physiology; Plasticity; Striatum; Synaptic Scaling
Abstract
Huntington disease is a genetic disorder caused by the inheritance of at least one mutated version of the huntingtin gene. Age of onset of Huntington disease is typically from the mid thirties to the late fourties, with motor, psychiatric and cognitive symptoms becoming progressively worse and culminating in death 15 to 20 years after disease onset. Disease onset is defined by the appearance of overt motor symptoms, most noticeably chorea: sudden, uncontrollable movements. Psychiatric symptoms begin 15 years before the onset of chorea and include anxiety, depression, paranoia, among other symptoms. They impact both the quality of life of patients and their ability to stay in the workforce, and are thought to be caused by malfunctioning connections between brain cells. Information in the brain is coded by the strength of the connections between cells. Through a process known as synaptic plasticity the connections between cells whose activity is often linked will increase, and the connections between cells whose activity is rarely linked will decrease. The strength of connections between these cells must be kept within a certain range. Cells which are too strongly connected will generate epileptic seizures, and cells which are too weakly connected will die. A group of processes known collectively as homeostatic plasticity work to keep the strength of connections between brain cells within this range. One of these processes is synaptic scaling, in which high levels of activity in a network of cells causes the strength of connections between all of the cells to decrease, and low levels of activity in a network causes the strength of connections between all of the cells to increase. Since some of the molecules whose function is changed in Huntington disease are also thought to to be involved in homeostatic plasticity, we suggest that homeostatic plasticity may be abnormal in Huntington disease. We will test this by growing cells from YAC128 mice, which carry mutant copies of the huntingtin gene, and FVB mice, which carry normal versions of the huntingtin gene, in dishes for three weeks. We will grow cells from two brain areas, the cortex and the striatum, the connections between which are especially badly affected in Huntington disease. We will then mix either tetrodotoxin, which will decrease the activity of the cells, bicuculline, which will increase the activity of the cells, or water, which should have no effect on the activity of the cells, into the cells' growth medium and let them grow under these conditions for 48 hours. After this we will measure the strength of the connections between the cells. We will do this in two ways: we will label certain molecules which are involved in transmitting information between cells and measure how many of them there are at the sites where cells connect with each other, and we will measure the electrical signals which are transmitted between cells. We will treat cells some cells with brain-derived neurotrophic factor, a molecule which is produced less by the brain cells of Huntington disease sufferers and is thought to be involved in controling homeostatic plasticity, to try to return homeostatic plasticity in cells from YAC128 to its healthy form. Understanding the biology underlying the early psychiatric symptoms of Huntington disease will allow us to develop new drugs to treat these symptoms. This will benefit Huntington disease sufferers by improving their quality of life. It will also benefit their social circle, as psychiatric disturbances can be disruptive to friends, family and loved ones as well as to the affected individual. Finally, it will benefit society by allowing Huntington disease sufferers to remain at work, contributing to the economy instead of incurring care costs, longer.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Smith-Dijak, Amy I
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~